Loading…

Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma

The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bor...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in medicine 2021-12, Vol.8, p.749863
Main Authors:	Cai, Jiao, Qiu, Ling, Ma, Lei, Zhang, Nan, Fan, Fang-Yi
Format:	Article
Language:	English
Subjects:	18F-FDG PET/CT autologous hematopoietic stem cell transplantation bortezomib lenalidomide Medicine plasmablastic lymphoma
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c429t-998cb6b38fcc6676e5ec018a1b8d77749f102bf96045d981d0a0de69928a2f8f3
cites	cdi_FETCH-LOGICAL-c429t-998cb6b38fcc6676e5ec018a1b8d77749f102bf96045d981d0a0de69928a2f8f3
container_end_page
container_issue
container_start_page	749863
container_title	Frontiers in medicine
container_volume	8
creator	Cai, Jiao Qiu, Ling Ma, Lei Zhang, Nan Fan, Fang-Yi
description	The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.
doi_str_mv	10.3389/fmed.2021.749863
format	article
fullrecord	<record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0b1136c191e8499ba4a5fd84606a74a7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_0b1136c191e8499ba4a5fd84606a74a7</doaj_id><sourcerecordid>34926499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-998cb6b38fcc6676e5ec018a1b8d77749f102bf96045d981d0a0de69928a2f8f3</originalsourceid><addsrcrecordid>eNpVUsFu1DAQtRCIVkvvnJB_IIvtJI7NAakNlFZa1IouEjdrHE92XTlxSLKg5av4RLwsVO1lbI09743ee4S85myZ50q_bTt0S8EEX1aFVjJ_Rk6F0DJTpfr2_NH9hJxN0z1jjOeiLHj-kpzkhRay0PqU_K5hQvoFhzjO7-hFqvgrdt7S27CbaP3h5pZexhDiT3TU7ukdft9hP3sI9Hw3xxA3MX27wg7mOESPs2_o3YwdrTEEuh6hn4YA_Qyzjz2F3tEV9hC8SxwOs4tE7uhn8P2c2n2DdL3FEYY99X3aAKYObKoH1NW-G7axg1fkRQthwrN_54J8vfy4rq-y1c2n6_p8lTWF0HOmtWqstLlqm0bKSmKJDeMKuFWuqpJgLWfCtlqyonRacceAOZRaCwWiVW2-INdHXBfh3gyj72Dcmwje_G3EcWNgTIsFNMxynsuGa44qiWqhgLJ1qpBMQlVAlbDeH7GGnU2mNUnBEcIT0Kcvvd-aTfxhlKwqnSxbEHYEaMY4TSO2D7OcmUMYzCEM5hAGcwxDGnnzmPNh4L_1-R8P3rWA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma</title><source>PubMed Central(OpenAccess)</source><creator>Cai, Jiao ; Qiu, Ling ; Ma, Lei ; Zhang, Nan ; Fan, Fang-Yi</creator><creatorcontrib>Cai, Jiao ; Qiu, Ling ; Ma, Lei ; Zhang, Nan ; Fan, Fang-Yi</creatorcontrib><description>The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.</description><identifier>ISSN: 2296-858X</identifier><identifier>EISSN: 2296-858X</identifier><identifier>DOI: 10.3389/fmed.2021.749863</identifier><identifier>PMID: 34926499</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>18F-FDG PET/CT ; autologous hematopoietic stem cell transplantation ; bortezomib ; lenalidomide ; Medicine ; plasmablastic lymphoma</subject><ispartof>Frontiers in medicine, 2021-12, Vol.8, p.749863</ispartof><rights>Copyright © 2021 Cai, Qiu, Ma, Zhang and Fan.</rights><rights>Copyright © 2021 Cai, Qiu, Ma, Zhang and Fan. 2021 Cai, Qiu, Ma, Zhang and Fan</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-998cb6b38fcc6676e5ec018a1b8d77749f102bf96045d981d0a0de69928a2f8f3</citedby><cites>FETCH-LOGICAL-c429t-998cb6b38fcc6676e5ec018a1b8d77749f102bf96045d981d0a0de69928a2f8f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677941/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677941/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34926499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cai, Jiao</creatorcontrib><creatorcontrib>Qiu, Ling</creatorcontrib><creatorcontrib>Ma, Lei</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Fan, Fang-Yi</creatorcontrib><title>Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma</title><title>Frontiers in medicine</title><addtitle>Front Med (Lausanne)</addtitle><description>The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.</description><subject>18F-FDG PET/CT</subject><subject>autologous hematopoietic stem cell transplantation</subject><subject>bortezomib</subject><subject>lenalidomide</subject><subject>Medicine</subject><subject>plasmablastic lymphoma</subject><issn>2296-858X</issn><issn>2296-858X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUsFu1DAQtRCIVkvvnJB_IIvtJI7NAakNlFZa1IouEjdrHE92XTlxSLKg5av4RLwsVO1lbI09743ee4S85myZ50q_bTt0S8EEX1aFVjJ_Rk6F0DJTpfr2_NH9hJxN0z1jjOeiLHj-kpzkhRay0PqU_K5hQvoFhzjO7-hFqvgrdt7S27CbaP3h5pZexhDiT3TU7ukdft9hP3sI9Hw3xxA3MX27wg7mOESPs2_o3YwdrTEEuh6hn4YA_Qyzjz2F3tEV9hC8SxwOs4tE7uhn8P2c2n2DdL3FEYY99X3aAKYObKoH1NW-G7axg1fkRQthwrN_54J8vfy4rq-y1c2n6_p8lTWF0HOmtWqstLlqm0bKSmKJDeMKuFWuqpJgLWfCtlqyonRacceAOZRaCwWiVW2-INdHXBfh3gyj72Dcmwje_G3EcWNgTIsFNMxynsuGa44qiWqhgLJ1qpBMQlVAlbDeH7GGnU2mNUnBEcIT0Kcvvd-aTfxhlKwqnSxbEHYEaMY4TSO2D7OcmUMYzCEM5hAGcwxDGnnzmPNh4L_1-R8P3rWA</recordid><startdate>20211203</startdate><enddate>20211203</enddate><creator>Cai, Jiao</creator><creator>Qiu, Ling</creator><creator>Ma, Lei</creator><creator>Zhang, Nan</creator><creator>Fan, Fang-Yi</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211203</creationdate><title>Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma</title><author>Cai, Jiao ; Qiu, Ling ; Ma, Lei ; Zhang, Nan ; Fan, Fang-Yi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-998cb6b38fcc6676e5ec018a1b8d77749f102bf96045d981d0a0de69928a2f8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>18F-FDG PET/CT</topic><topic>autologous hematopoietic stem cell transplantation</topic><topic>bortezomib</topic><topic>lenalidomide</topic><topic>Medicine</topic><topic>plasmablastic lymphoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cai, Jiao</creatorcontrib><creatorcontrib>Qiu, Ling</creatorcontrib><creatorcontrib>Ma, Lei</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Fan, Fang-Yi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cai, Jiao</au><au>Qiu, Ling</au><au>Ma, Lei</au><au>Zhang, Nan</au><au>Fan, Fang-Yi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma</atitle><jtitle>Frontiers in medicine</jtitle><addtitle>Front Med (Lausanne)</addtitle><date>2021-12-03</date><risdate>2021</risdate><volume>8</volume><spage>749863</spage><pages>749863-</pages><issn>2296-858X</issn><eissn>2296-858X</eissn><abstract>The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>34926499</pmid><doi>10.3389/fmed.2021.749863</doi><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2296-858X
ispartof	Frontiers in medicine, 2021-12, Vol.8, p.749863
issn	2296-858X 2296-858X
language	eng
recordid	cdi_doaj_primary_oai_doaj_org_article_0b1136c191e8499ba4a5fd84606a74a7
source	PubMed Central(OpenAccess)
subjects	18F-FDG PET/CT autologous hematopoietic stem cell transplantation bortezomib lenalidomide Medicine plasmablastic lymphoma
title	Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T08%3A09%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Case%20Report:%20Bortezomib%20Plus%20CDOP%20Followed%20by%20Sequential%20Autologous%20Hematopoietic%20Stem%20Cell%20Transplantation%20and%20Lenalidomide-Based%20Maintenance%20Therapy%20in%20Plasmablastic%20Lymphoma&rft.jtitle=Frontiers%20in%20medicine&rft.au=Cai,%20Jiao&rft.date=2021-12-03&rft.volume=8&rft.spage=749863&rft.pages=749863-&rft.issn=2296-858X&rft.eissn=2296-858X&rft_id=info:doi/10.3389/fmed.2021.749863&rft_dat=%3Cpubmed_doaj_%3E34926499%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-998cb6b38fcc6676e5ec018a1b8d77749f102bf96045d981d0a0de69928a2f8f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/34926499&rfr_iscdi=true